FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

,	rvasilington,	D.C.	20349	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burd	den							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Sepp-Lorenzino Laura</u>					2. Issuer Name and Ticker or Trading Symbol Intellia Therapeutics, Inc. [NTLA]						5. Relationship of Reporting Person(s) to Issu (Check all applicable) Director 10% Ow Officer (give title Other (s				ner	
(Last) (First) (Middle) C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130					3. Date of Earliest Transaction (Month/Day/Year) 06/03/2019						k below) EVP, Chief Scientific Officer				Jecliy	
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Lir	e) X Form fi Form fi	dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date					Execu		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		ed (A) or str. 3, 4 and	Beneficia Owned F	s Form ally (D) or following (I) (In		n: Direct I r Indirect E nstr. 4) (7. Nature of ndirect Beneficial Ownership
									Amount	(A) o (D)	r Price	Reported Transact (Instr. 3 a	ion(s)			nstr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	Conversion Date Execut or Exercise (Month/Day/Year) if any		3A. Deemed Execution Date, if any (Month/Day/Year)	rate, Transaction Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and of Securities Underlying Derivative S (Instr. 3 and		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share	S	(Instr. 4)	Jii(3)		
Stock Option (Right to Buy)	\$14.25	06/03/2019		A		150,000		(1)	05/27/2029	Common Stock	150,00	\$0.00	150,00	0	D	

Explanation of Responses:

1. This option was granted on May 28, 2019 with respect to 150,000 shares of Common Stock, with 25% vesting on May 28, 2020 and the remainder vesting in thirty-six equal monthly installments thereafter.

Remarks:

/s/ Jose Rivera, Attorney-In-

06/04/2019

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.